As EURIE Summit 2022 will be a hybrid event, in-person participation will include all the virtual elements of the event, plus additional face-to-face activities in Istanbul. In-person participants will have access to the EURIE Virtual Event Platform which will host online conference sessions and the Virtual Exhibiton Hall for networking. Additionally, in-person participants will be able to attend the Opening Ceremony, face-to-face workshops, special networking sessions, campus tours and FAM trips in Istanbul.
Registration fee for In-person Participation includes;
- Online access to live panel sessions
- Online access to live plenary sessions by prominent speakers
- On-demand viewing of conference sessions for 1 month after the conference
- Online access to the Virtual Exhibition Hall with live video chat options
- Additional online networking and video chat options via the EURIE Virtual Event Platform
- Opening Ceremony on-site
- Face-to-face workshops on-site
- Face-to-face special networking sessions and roundtables on-site
- Campus tours to EURIE-partner universities in Istanbul
- FAM trips to EURIE-partner universities in Istanbul
- Every precaution possible will be taken to create a safe environment for participants attending on-site. In-person activities will be organized in accordance with Turkish Ministry of Health regulations and WHO guidelines for public gatherings during the COVID-19 pandemic.
- EURIE 2022 official travel agent Boyut group will provide timely information about travel restrictions, quarantine requirements, and vaccinations/ testing mandates for in-person participation. They will provide accommodation and airport transfer packages for your health and convenience. If the conditions do not allow the conference to be held on-site as expected, the event will shift to a fully virtual format. Whether in-person participation is cancelled by the organizers or the participant, the difference between in-person and online registration fee will be refunded.
Health and Safety issues in relation to COVID-19.